Despite setbacks, Pfizer Inc. believes its oral GLP-1 agonist danuglipron remains in a competitive position versus rivals. Investors are hyper-focused on the development of danuglipron for obesity, even though it remains relatively early days, because of the multibillion-dollar market opportunity and the fast-changing competitive dynamics.
Pfizer Bullish On Danuglipron’s Position In Oral GLP-1 Race
The company believes it still has a good shot at getting an oral GLP-1 to market ahead of many competitors, if not necessarily ahead of Lilly.
More from Earnings
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
More from Business
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.